Posted on TD today. So much for rumors
4 hours ago by MT Newswires
10:25 AM EDT, 03/15/2021 (MT Newswires) -- Aeterna Zentaris Inc. (AEZS.TO) through its wholly-owned subsidiary Aeterna Zentaris GmbH, has exercised its option and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-19 vaccine currently in preclinical development at the Julius-Maximilians-University Wuerzburg in Germany.. Additionally, the company has entered into a research agreement with the University to conduct supplementary research activities and preclinical development studies on the potential vaccine.
The company will pay an up-front payment of 140,000 euros and certain milestones payments that will be paid when certain development, and regulatory and sales milestones are reached. Aerterna will also pay a percentage of any sub-licensing revenue it receives and royalty payments on net sales of the licensed vaccine product.
The vaccine technology developed at the University uses the approved typhoid fever vaccine Salmonella Typhi Ty21a as a carrier strain and has the potential to be an orally active, live-attenuated bacterial vaccine to prevent COVID-19 infection.
"Over the last months, we learned that the original SARS-CoV-2 strain mutates rapidly, and these mutant strains continue to spread throughout the population. It has been reported that the currently available vaccines for COVID-19 are still effective against the known mutant strains. However, we believe there is the potential to develop an improved vaccine which relies on several SARS-CoV-2 antigens in parallel with the goal of improving the immune response against mutated viruses. Additionally, our vaccine has the potential to become a cost-effective oral alternative with less demanding storage and logistics requirements," said Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris.
Price: 1.69, Change: +0.22, Percent Change: +14.97
4 hours ago by MT Newswires
10:25 AM EDT, 03/15/2021 (MT Newswires) -- Aeterna Zentaris Inc. (AEZS.TO) through its wholly-owned subsidiary Aeterna Zentaris GmbH, has exercised its option and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-19 vaccine currently in preclinical development at the Julius-Maximilians-University Wuerzburg in Germany.. Additionally, the company has entered into a research agreement with the University to conduct supplementary research activities and preclinical development studies on the potential vaccine.
The company will pay an up-front payment of 140,000 euros and certain milestones payments that will be paid when certain development, and regulatory and sales milestones are reached. Aerterna will also pay a percentage of any sub-licensing revenue it receives and royalty payments on net sales of the licensed vaccine product.
The vaccine technology developed at the University uses the approved typhoid fever vaccine Salmonella Typhi Ty21a as a carrier strain and has the potential to be an orally active, live-attenuated bacterial vaccine to prevent COVID-19 infection.
"Over the last months, we learned that the original SARS-CoV-2 strain mutates rapidly, and these mutant strains continue to spread throughout the population. It has been reported that the currently available vaccines for COVID-19 are still effective against the known mutant strains. However, we believe there is the potential to develop an improved vaccine which relies on several SARS-CoV-2 antigens in parallel with the goal of improving the immune response against mutated viruses. Additionally, our vaccine has the potential to become a cost-effective oral alternative with less demanding storage and logistics requirements," said Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris.
Price: 1.69, Change: +0.22, Percent Change: +14.97